Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by FredTheVoiceon Feb 03, 2020 2:11pm
80 Views
Post# 30635267

Canadian press/ HIV

Canadian press/ HIV
Here is the link of the original version;

 https://www.lapresse.ca/actualites/sante/202002/03/01-5259375-des-chercheurs-tentent-une-nouvelle-approche-face-au-vih.php


Translation follows:


(Montreal) Immunotherapy combining two anti-HIV antibodies seems to be able to reduce the viral load with an effectiveness similar to antiretroviral treatment (ARV), says an international team of researchers.
 
Posted on February 03, 2020, at 11:05 a.m. Share
THE CANADIAN PRESS
 
In a study published in Nature Medicine, researchers from the Research Center of the Center hospitalier de l'Universit de Montral, Rockefeller University and the University of Cologne describe how the injection of these powerful anti-HIV antibodies, or antibodies neutralizers, is associated with a strengthening of the response of T lymphocytes which specifically recognize the virus.
T cells are important blood cells that help control chronic infections such as HIV. This study shows an unexpected interaction and a potential influence between two parts of the human immune system: humoral immunity (antibodies) and cell-mediated immunity (T lymphocytes).
Two days before stopping antiretroviral therapy, nine people living with HIV and hosts of antibody-sensitive viruses received a first injection of a combination of two antibodies. Recruited by an international research team, this cohort of patients received new antibody injections after three and six weeks of follow-up. Blood tests were done weekly to check for a possible re-emergence of the virus.
 
The researchers observed that in the absence of ARV therapy, the activity level of CD4 and CD8 T cells, which respond specifically to HIV, increased during the period of treatment with the antibodies.
In the future, the statement added, this type of antibody therapy will be studied in larger clinical studies to prevent or treat HIV, because antibodies are very well tolerated by humans and can effectively block the virus for many weeks.
According to the World Health Organization, approximately 37.9 million people were living with HIV at the end of 2018.


FTV.
Bullboard Posts